Brought to you by 
AstraZeneca buys Probiodrug's CDK9 inhibitor program
18 Nov 2022
Executive Summary
Further strengthening its oncology and inflammatory disease pipeline, AstraZeneca PLC acquired an early-stage cyclin-dependent kinase 9 (CDK9) inhibitor program from Probiodrug AG (developing therapies for Alzheimer’s disease).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Product Purchase
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AstraZeneca buys Probiodrug's CDK9 inhibitor program
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice